Pharmorubicin PFS

3-glycoloyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1-naphthacenyl-3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside hydrochloride

(8S-cis)-10-((3-amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione hydrochloride

Ellence

IMI-28

The hydrochloride salt of the 4'-epi-isomer of the anthracycline antineoplastic antibiotic doxorubicin. Epirubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C474" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C474" NCI Thesaurus)

http://purl.bioontology.org/ontology/PDQ/CDR0000039232

Pharmorubicin PFS

3-glycoloyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1-naphthacenyl-3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside hydrochloride

(8S-cis)-10-((3-amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione hydrochloride

Ellence

IMI-28

56390-09-1

http://purl.bioontology.org/ontology/PDQ/CDR0000041952

http://purl.bioontology.org/ontology/PDQ/CDR0000299016

http://purl.bioontology.org/ontology/PDQ/CDR0000038163

http://purl.bioontology.org/ontology/PDQ/CDR0000042531

http://purl.bioontology.org/ontology/PDQ/CDR0000038677

http://purl.bioontology.org/ontology/PDQ/CDR0000306041

http://purl.bioontology.org/ontology/PDQ/CDR0000372882

http://purl.bioontology.org/ontology/PDQ/CDR0000288841

http://purl.bioontology.org/ontology/PDQ/CDR0000042354

http://purl.bioontology.org/ontology/PDQ/CDR0000038347

http://purl.bioontology.org/ontology/PDQ/CDR0000042530

http://purl.bioontology.org/ontology/PDQ/CDR0000039767

http://purl.bioontology.org/ontology/PDQ/CDR0000040590

http://purl.bioontology.org/ontology/PDQ/CDR0000415568

http://purl.bioontology.org/ontology/PDQ/CDR0000042607

http://purl.bioontology.org/ontology/PDQ/CDR0000040994

http://purl.bioontology.org/ontology/PDQ/CDR0000042569

http://purl.bioontology.org/ontology/PDQ/CDR0000042465

http://purl.bioontology.org/ontology/PDQ/CDR0000042621

http://purl.bioontology.org/ontology/PDQ/CDR0000040993

http://purl.bioontology.org/ontology/PDQ/CDR0000438791

http://purl.bioontology.org/ontology/PDQ/CDR0000041002

http://purl.bioontology.org/ontology/PDQ/CDR0000041282

http://purl.bioontology.org/ontology/PDQ/CDR0000042162

http://purl.bioontology.org/ontology/PDQ/CDR0000038679

http://purl.bioontology.org/ontology/PDQ/CDR0000038319

http://purl.bioontology.org/ontology/PDQ/CDR0000042710

http://purl.bioontology.org/ontology/PDQ/CDR0000038207

http://purl.bioontology.org/ontology/PDQ/CDR0000040491

http://purl.bioontology.org/ontology/PDQ/CDR0000037864

http://purl.bioontology.org/ontology/PDQ/CDR0000041651

http://purl.bioontology.org/ontology/PDQ/CDR0000042409

http://purl.bioontology.org/ontology/PDQ/CDR0000043485

http://purl.bioontology.org/ontology/PDQ/CDR0000038152

http://purl.bioontology.org/ontology/PDQ/CDR0000374712

http://purl.bioontology.org/ontology/PDQ/CDR0000042412

http://purl.bioontology.org/ontology/PDQ/CDR0000041954

http://purl.bioontology.org/ontology/PDQ/CDR0000040995

http://purl.bioontology.org/ontology/PDQ/CDR0000410765

http://purl.bioontology.org/ontology/PDQ/CDR0000041583

http://purl.bioontology.org/ontology/PDQ/CDR0000038586

http://purl.bioontology.org/ontology/PDQ/CDR0000041763

http://purl.bioontology.org/ontology/PDQ/CDR0000043231

http://purl.bioontology.org/ontology/PDQ/CDR0000322130

http://purl.bioontology.org/ontology/PDQ/CDR0000038343

C0282387

C1516927

C0700582

C0701345

2017-10-26

The hydrochloride salt of the 4'-epi-isomer of the anthracycline antineoplastic antibiotic doxorubicin. Epirubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C474" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C474" NCI Thesaurus)

1854

TRD

C474

CDR0000039232

256942

Drug/agent

epirubicin hydrochloride

T109

T121